Results 91 to 100 of about 11,948 (164)

Oral JAK Inhibitors as a Promising Therapeutic Strategy for Refractory Rosacea: A Systematic Review and Meta‐Analysis

Journal of Cosmetic Dermatology, Volume 25, Issue 3, March 2026.
ABSTRACT Background Rosacea is a chronic inflammatory dermatosis. While standard therapies exist, managing refractory subtypes remains a therapeutic challenge. Oral Janus kinase (JAK) inhibitors have emerged as potential alternatives, but systematic evidence is lacking. Aims To evaluate the efficacy and safety of oral JAK inhibitors for rosacea through
Yu Peng, Mingzi Sun, Jiayu Chen, Xubo Huang, Fengchuan Zhang   +4 more
wiley   +1 more source

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients. [PDF]

Rheumatol Ther
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Östör A, Ng KJ, Gerwien J, Zaremba-Pechmann L, Brnabic AJM, Fautrel B.   +9 more
europepmc   +1 more source

Beard hair response in alopecia areata universalis treated with baricitinib. [PDF]

JAAD Int
Trecarichi AC, Amato A, Lacarrubba F, Micali G, Dall'Oglio F.   +4 more
europepmc   +1 more source

Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy. [PDF]

Clin Pract
Matteini E, Artosi F, Caldarola G, Pinto LM, Rossi A, Ala L, Costanza G, Bianchi L, Campione E, Diluvio L.   +9 more
europepmc   +1 more source

Issue Information

JEADV Clinical Practice, Volume 5, Issue 1, Page 1-6, March 2026.
wiley   +1 more source

Case Report: A case of autoinflammatory disease with a novel <i>NLRP12</i> variant-clinical presentation and successful treatment with baricitinib. [PDF]

Front Med (Lausanne)
Wang W, Li Q, Ma X, Zhou L, Ge D, Fan H, Jiang H, Shi X.   +7 more
europepmc   +1 more source

Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance. [PDF]

Front Med (Lausanne)
Zheng R, Lu J, Deng M, Lyu J, Han J, Chen J, Wang Q, Liu Y, Yuan L, Bai Z.   +9 more
europepmc   +1 more source

Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report. [PDF]

Case Reports Hepatol
Kim GE, Imran M, Mostafa S, Kamel Y.
europepmc   +1 more source

Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database. [PDF]

Front Public Health
Kong L, Liu X, Feng Y.
europepmc   +1 more source

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study. [PDF]

RMD Open
Temiz A, Tascilar K, Kleyer A, Hueber AJ, Hartmann F, Schett G, Bayat S.   +6 more
europepmc   +1 more source